Clinical trial
Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.
NCT00479934 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.
- Lead sponsor
- University Hospital, Bordeaux
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- December 31, 2010
- Enrollment
- 28 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.